PL1968592T3 - Preparaty zawierające związki pokrewne jorumycyny, renieramycyny, safracyny lub saframycyny oraz dwucukier do leczenia chorób proliferacyjnych - Google Patents

Preparaty zawierające związki pokrewne jorumycyny, renieramycyny, safracyny lub saframycyny oraz dwucukier do leczenia chorób proliferacyjnych

Info

Publication number
PL1968592T3
PL1968592T3 PL06795019T PL06795019T PL1968592T3 PL 1968592 T3 PL1968592 T3 PL 1968592T3 PL 06795019 T PL06795019 T PL 06795019T PL 06795019 T PL06795019 T PL 06795019T PL 1968592 T3 PL1968592 T3 PL 1968592T3
Authority
PL
Poland
Prior art keywords
formulations
jorumycin
renieramycin
safracin
saframycin
Prior art date
Application number
PL06795019T
Other languages
English (en)
Inventor
Salve Pilar Calvo
Barreira María Tobio
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of PL1968592T3 publication Critical patent/PL1968592T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL06795019T 2005-10-31 2006-10-30 Preparaty zawierające związki pokrewne jorumycyny, renieramycyny, safracyny lub saframycyny oraz dwucukier do leczenia chorób proliferacyjnych PL1968592T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0522082.7A GB0522082D0 (en) 2005-10-31 2005-10-31 Formulations
PCT/GB2006/050362 WO2007052076A2 (en) 2005-10-31 2006-10-30 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases
EP06795019A EP1968592B1 (en) 2005-10-31 2006-10-30 Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds and a disaccharide for treating proliferative diseases

Publications (1)

Publication Number Publication Date
PL1968592T3 true PL1968592T3 (pl) 2012-08-31

Family

ID=35515969

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06795019T PL1968592T3 (pl) 2005-10-31 2006-10-30 Preparaty zawierające związki pokrewne jorumycyny, renieramycyny, safracyny lub saframycyny oraz dwucukier do leczenia chorób proliferacyjnych

Country Status (24)

Country Link
US (1) US9192568B2 (pl)
EP (1) EP1968592B1 (pl)
JP (1) JP5197373B2 (pl)
KR (1) KR101434230B1 (pl)
CN (1) CN101300011B (pl)
AT (1) ATE549023T1 (pl)
AU (1) AU2006310260C1 (pl)
CA (1) CA2625096C (pl)
DK (1) DK1968592T3 (pl)
ES (1) ES2383967T3 (pl)
GB (1) GB0522082D0 (pl)
HK (1) HK1122743A1 (pl)
HR (1) HRP20120478T1 (pl)
IL (1) IL190774A (pl)
NO (1) NO341057B1 (pl)
NZ (1) NZ567291A (pl)
PL (1) PL1968592T3 (pl)
PT (1) PT1968592E (pl)
RS (1) RS52312B (pl)
RU (1) RU2429845C2 (pl)
SI (1) SI1968592T1 (pl)
UA (1) UA97629C2 (pl)
WO (1) WO2007052076A2 (pl)
ZA (1) ZA200803420B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
NZ589269A (en) * 2008-05-16 2013-03-28 Pharma Mar Sa Combination therapy with an antitumor alkaloid
KR20110028454A (ko) * 2008-05-16 2011-03-18 파르마 마르 에스.에이. 다발성 골수종 치료법
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
WO2012146625A1 (en) * 2011-04-28 2012-11-01 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
EP2928463B1 (en) 2012-10-26 2019-11-20 Oncopeptides AB Lyophilized preparations of melphalan flufenamide
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
US10526334B2 (en) 2017-07-19 2020-01-07 California Institute Of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds
JPWO2022186221A1 (pl) * 2021-03-03 2022-09-09

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
DE19605212A1 (de) * 1996-02-13 1997-08-14 Basf Ag Phosphordotiertes Silberkatalysator-Festbett
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
AU7589898A (en) 1997-05-21 1998-12-11 Genentech Inc. Novel administration of thrombopoietin
IL138856A0 (en) * 1998-04-06 2001-10-31 Univ Illinois Semi-synthetic ecteinascidins
US6316214B1 (en) 1998-05-11 2001-11-13 The Board Of Trustees Of The University Of Illinois ETM-775 metabolite of ecteinascidin 743
JP2000081438A (ja) 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
PT1280809E (pt) 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
WO2002014554A2 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
DK1330258T3 (da) * 2000-10-31 2006-05-22 Pharma Mar Sa Kahalalid F-formulering
CA2447553A1 (en) * 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
KR20030071853A (ko) 2001-01-25 2003-09-06 브리스톨-마이어스스퀴브컴파니 에포틸론 유사체를 함유한 비경구용 제제
EP1360337A1 (en) * 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
YU69903A (sh) * 2001-03-06 2006-08-17 Bristol-Myers Squibb Company Postupak i dozni oblik za lečenje tumora primenom tegafura, uracila, folne kiseline, paklitaksela i karboplatina
EP1372658A2 (en) 2001-03-30 2004-01-02 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20050004018A1 (en) * 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7251892B2 (en) * 2003-07-09 2007-08-07 Temper Corporation Bearing assembly spacer adjustable system and method for adjusting a spacer
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DE602004016376D1 (de) 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
WO2005049030A1 (en) 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2005118584A2 (en) * 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
EP1768671A2 (en) * 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
WO2006035244A2 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
SI1827500T1 (sl) 2004-10-26 2009-10-31 Pharma Mar Sa Pegiliran liposomski doksorubicin v kombinaciji s ekteinescidinom 743
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
WO2006066183A2 (en) * 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
CA2630900A1 (en) * 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
JP2009536956A (ja) * 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法

Also Published As

Publication number Publication date
IL190774A0 (en) 2008-11-03
EP1968592A2 (en) 2008-09-17
SI1968592T1 (sl) 2012-10-30
CA2625096C (en) 2015-11-24
AU2006310260C1 (en) 2013-09-19
AU2006310260A1 (en) 2007-05-10
DK1968592T3 (da) 2012-07-02
WO2007052076A3 (en) 2008-03-20
US20090076016A1 (en) 2009-03-19
UA97629C2 (ru) 2012-03-12
ES2383967T3 (es) 2012-06-27
CN101300011A (zh) 2008-11-05
NZ567291A (en) 2011-04-29
NO341057B1 (no) 2017-08-14
ZA200803420B (en) 2009-10-28
NO20082425L (no) 2008-07-25
PT1968592E (pt) 2012-06-18
US9192568B2 (en) 2015-11-24
CA2625096A1 (en) 2007-05-10
WO2007052076A2 (en) 2007-05-10
GB0522082D0 (en) 2005-12-07
IL190774A (en) 2013-11-28
CN101300011B (zh) 2011-12-28
JP5197373B2 (ja) 2013-05-15
HK1122743A1 (en) 2009-07-17
KR101434230B1 (ko) 2014-08-26
EP1968592B1 (en) 2012-03-14
JP2009513618A (ja) 2009-04-02
ATE549023T1 (de) 2012-03-15
RS52312B (en) 2012-12-31
RU2008121716A (ru) 2009-12-10
RU2429845C2 (ru) 2011-09-27
KR20080064959A (ko) 2008-07-10
HRP20120478T1 (hr) 2012-07-31
AU2006310260B2 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
JO2464B1 (en) Formulas contain actinacidine and binary sugars
HK1122743A1 (en) Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin- related compounds and a disaccharide for treating proliferative diseases
WO2009105513A8 (en) Novel compounds and methods for therapy
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
WO2007059008A3 (en) N-substituted indenoisoquinolines and syntheses thereof
MY152283A (en) Polo-like kinase inhibitirs
EP2046735A4 (en) SUBSTITUTED PHENYL SULFUR TRIFLUORIDE AND OTHER SIMILAR FLUORINATING SUBSTANCES
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
SG148192A1 (en) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
WO2008027600A3 (en) Imatinib compositions
TNSN08069A1 (en) Amorphous solid dispersions of 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5,-dihydro-4h-pyridazino[4,5 b] indole -1- acetamide
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
SI2020410T1 (sl) Derivati pirido(2,3-d)pirimidina, njihova priprava, njihova terapevtska uporaba
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
EP2059503A4 (en) AMINO-PYRAZOL DERIVATIVES, PREPARATION METHOD AND PREPARATION THEREFOR FOR PREVENTION OR TREATMENT OF ISCHEMIC ILLNESSES
IL200000A (en) Process for Preparing 5- (1- Alkylthio) Alkylpyridines are Stored in Position 2 and Its Compounds
SG152296A1 (en) Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one
TW200738236A (en) Certain chemical entities, compositions, and methods
GB0515025D0 (en) Organic compounds
TW200640836A (en) Processes for preparing sertraline
IL186457A0 (en) Process for the preparation of 9,10-dehydro-12,13-desoxyepothilone derivatives
HK1113675A1 (en) Derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
TW200637813A (en) Process for the preparation of Fenoldopam mesylate